Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer

Journal of Infectious Diseases

Volumn 204, Issue 10, 2011, Pages 1475-1482

  Carr, Silvana ^a,f   Allison, Kim J ^a   Van De Velde, Lee Ann ^a   Zhang, Kelly ^a   English, Elizabeth Y ^a   Iverson, Amy ^a   Daw, Najat C ^b,g   Howard, Scott C ^b,d   Navid, Fariba ^b,d   Rodriguez Galindo, Carlos ^b,h   Yang, Jie ^a   Adderson, Elisabeth E ^a,c,d   Mccullers, Jonathan A ^a,c   Flynn, Patricia M ^a,d,e  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Departments of Oncology   (United States)

^c Departments of Molecular Sciences   (United States)

^d Departments of Pediatrics   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLUENZA VACCINE; LIVE ATTENUATED INFLUENZA VACCINE; OSELTAMIVIR; SODIUM; TRIVALENT INACTIVATED INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; BLOOD SAMPLING; CANCER PATIENT; CELLULAR IMMUNITY; CHILD; CHILL; CONFERENCE PAPER; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HOSPITALIZATION; HUMAN; HYPOTENSION; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INJECTION SITE REACTION; IRRITABILITY; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; MYALGIA; NOSE SMEAR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SEIZURE; SEROCONVERSION; SIDE EFFECT; SORE THROAT; T LYMPHOCYTE; VIRUS CULTURE; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS SHEDDING; VOMITING;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; NEOPLASMS; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VIRUS SHEDDING; YOUNG ADULT;

EID: 80054734187     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir561     Document Type: Conference Paper

References (44)

1. Glezen WP, Paredes A, Taber LH. Influenza in children. Relationship to other respiratory agents. JAMA 1980; 243:1345-9. (Pubitemid 10129068)
2. Neuzil KM, Wright PF, Mitchel EF Jr, Griffin MR. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr 2000; 137:856-64.
3. Apalsch AM, Green M, Ledesma-Medina J, Nour B, Wald ER. Parainfluenza and influenza virus infections in pediatric organ transplant recipients. Clin Infect Dis 1995; 20:394-9.
4. Kempe A, Hall CB, MacDonald NE, et al. Influenza in children with cancer. J Pediatr 1989; 115:33-9. (Pubitemid 19177963)
5. Feldman S, Webster RG, Sugg M. Influenza in children and young adults with cancer: 20 cases. Cancer 1977; 39:350-3. (Pubitemid 8027746)
6. Potter MN, Foot AB, Oakhill A. Influenza A and the virus associated haemophagocytic syndrome: cluster of three cases in children with acute leukaemia. J Clin Pathol 1991; 44:297-9.
7. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004; 53:1-40.
8. Chisholm JC, Devine T, Charlett A, Pinkerton CR, Zambon M. Response to influenza immunisation during treatment for cancer. Arch Dis Child 2001; 84:496-500. (Pubitemid 33027590)
9. Porter CC, Edwards KM, Zhu Y, Frangoul H. Immune responses to influenza immunization in children receiving maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 2004; 42:36-40. (Pubitemid 38173455)
10. Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 22:295-302. (Pubitemid 26056158)
11. Stiver HG, Weinerman BH. Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients. Can Med Assoc J 1978; 119:733-5738.
12. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: A randomized controlled trial. JAMA 1999; 282:137-44. (Pubitemid 29323803)
13. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998; 338:1405-12. (Pubitemid 28221981)
14. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000; 136:168-75. (Pubitemid 30470986)
15. Tam JS, Capeding MR, Lum LC, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against cultureconfirmed influenza in young children in Asia. Pediatr Infect Dis J 2007; 26:619-28. (Pubitemid 47014164)
16. GaglaniMJ, Piedra PA, Herschler GB, et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 2004; 158:65-73.
17. Bracco Neto H, Farhat CK, Tregnaghi MW, et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 2009; 28:365-71.
18. Ambrose CS, Yi T, Walker RE, Connor EM. Duration of protection provided by live attenuated influenza vaccine in children. Pediatr Infect Dis J 2008; 27:744-8.
19. He XS, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006; 80:11756-66. (Pubitemid 44788888)
20. Halasa N, Englund JA, Nachman S, et al. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine 2011; 29:4110-5.
21. Centers for Disease Control and Prevention (CDC). Update: influenza activitydUnited States, September 28, 2008-January 31, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:115-9.
22. McCullers JA, Van De Velde LA, Allison KJ, Branum KC, Webby RJ, Flynn PM. Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis 2010; 50:1487-92.
23. Andreansky SS, Stambas J, Thomas PG, Xie W, Webby RJ, Doherty PC. Consequences of immunodominant epitope deletion for minor influenza virus-specific CD8+-T-cell responses. J Virol 2005; 79:4329-39. (Pubitemid 40388370)
24. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49:1373-9. (Pubitemid 27028925)
25. Vesikari T, Fleming DM, Aristegui JF, et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against communityacquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006; 118:2298-312. (Pubitemid 46397567)
26. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181:1133-7. (Pubitemid 30194502)
27. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513-22. (Pubitemid 44917499)
28. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006; 12:48-54. (Pubitemid 43143535)
29. Forrest BD, Pride MW, Dunning AJ, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008; 15: 1042-53. (Pubitemid 352018317)
30. Sato S, Nagai H. The clinical application of quantiferon TB-2G: its usefulness and limitations. Kekkaku 2011; 86:101-12.
31. Centers for Disease Control and Prevention. Update: influenza activity-United States and worldwide, 2005-06 season, and composition of the 2006-07 influenza vaccine. MMWR Morb Mortal Wkly Rep 2006; 55:648-53.
32. Centers for Disease Control and Prevention. Update: influenza activity-United States, September 30, 2007-February 9, 2008. MMWR Morb Mortal Wkly Rep 2008; 57:179-83.
33. Sanchez-Fructuoso AI, Prats D, Naranjo P, et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation 2000; 69: 436-9. (Pubitemid 30118129)
34. Smith KG, Isbel NM, Catton MG, Leydon JA, Becker GJ, Walker RG. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998; 13:160-4. (Pubitemid 28033597)
35. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: A consecutive 3-year study. Vaccine 2000; 18:3040-9. (Pubitemid 30303809)
36. Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 2006; 194: 1032-9. (Pubitemid 44547642)
37. Gross PA, Lee H, Wolff JA, Hall CB, Minnefore AB, Lazicki ME. Influenza immunization in immunosuppressed children. J Pediatr 1978; 92:30-5. (Pubitemid 8287920)
38. Matsuzaki A, Suminoe A, Koga Y, Kinukawa N, Kusuhara K, Hara T. Immune response after influenza vaccination in children with cancer. Pediatr Blood Cancer 2005; 45:831-7. (Pubitemid 41416495)
39. McMahon AW, Iskander JK, Haber P, Braun MM, Ball R. Inactivated influenza vaccine (IIV) in children ,2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine. Vaccine 2008; 26:427-9.
40. Kelly H, Carcione D, Dowse G, Effler P. Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010. Euro Surveill 2010; 15:19661.
41. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl JMed 2007; 356:685-96.
42. Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: The pediatric experience. Pediatr Infect Dis J 2001; 20: 733-40.
43. Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008; 26:4940-6.
44. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, doubleblind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 2006; 25:590-5. (Pubitemid 43995354)